[Fibrates in the light of large clinical trials].
Peroxisome proliferator-activated receptor (PPAR)α activators (fibrates) are one of the major group of hypolipidemic agents, that have been presented to have clinical benefits in prevention and treatment of cardiovascular disorders. Apart from their well-known hypolipidemic properties, fibrates produce other so-called pleiotropic effects, including anti-inflammatory and anti-oxidant action, as well as reduction in procoagulant activity and improvement in endothelial function. These observations are in line with some of the results from large randomised clinical trials, which indicated the benefits from therapy with fibrates other than we could expect from their hypolipidemic properties. Nevertheless, the analysis of these studies supports the argument that patients with mixed dyslipidemia and carbohydrate metabolism disturbances are the group, which benefits the most from fibrate therapy. In this article, particular attention is devoted to the results of the large clinical trials. We try to explain the differences between the results of various studies.
Medical University of Silesia in Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
Robert
R
Krysiak
Municipal Hospital in Ruda ŚlĄska, Poland, II Department of Internal Medicine and Diabetology.
Henryk
H
Rudzki
Medical University of Silesia in Katowice, Poland: Department of Internal Medicine and Metabolic Diseases.
Gabriela
G
Handzlik-Orlik
Medical University of Silesia in Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
Anna
A
Gdula-Dymek
Medical University of Silesia in Katowice, Poland: Department of Internal Medicine and Clinical Pharmacology.
BogusŁaw
B
Okopień
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D058607:Fibric Acids / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D014280:Triglycerides / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D014280:Triglycerides
PPARα receptor; fibrates; hemostasis; large clinical trials; pleiotropic effects